Prostate Cell News Volume 9.21 | Jun 8 2018

TOP STORY

ATR Inhibition Controls Aggressive Prostate Tumors Deficient in Y-Linked Histone Demethylase KDM5D

Scientists showed that loss of the male-specific histone demethylase lysine-specific demethylase 5D (KDM5D) encoded on the Y chromosome epigenetically modifies histone methylation marks and alters gene expression, resulting in aggressive prostate cancer. [J Clin Invest] Full Article

(Ranked by impact factor of the journal)

Oncogenic Properties of NEAT1 in Prostate Cancer Cells Depend on the CDC5L-AGRN Transcriptional Regulation Circuit

Researchers confirmed that repression of nuclear enriched abundant transcript 1 (NEAT1) induces DNA damage, disturbs the cell cycle, and arrests the proliferation of prostate cancer cells. Silencing NEAT1 in prostate cancer cells repressed the transcriptional activity of CDC5L, and RNA-seq and ChIP-seq analyses further revealed a handful of potential targets of CDC5L regulated by NEAT1 expression. [Cancer Res] Abstract

Protective Effect of Stromal Dickkopf-3 in Prostate Cancer: Opposing Roles for TGFBI and ECM-1

Investigators showed that dickkopf-3 (Dkk-3) silencing in WPMY-1 prostate stromal cells increased transforming growth factor–β (TGF-β) signaling activity and that stromal cell-conditioned media inhibited prostate cancer cell invasion in a Dkk-3-dependent manner. [Oncogene] Full Article

Epithelial Membrane Protein 1 Promotes Tumor Metastasis by Enhancing Cell Migration via Copine-III and Rac1

Using a co-culture assay system with human prostate cancer LNCaP cells and primary human prostate stromal cells, scientists identified epithelial membrane protein 1 as a gene with elevated expression in the cancer cells. [Oncogene] Full Article

Specific ¹⁸F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models is Facilitated by Pre-Binding to Sex Hormone Binding Globulin

Three human prostate cancer cell lines and xenografts were utilized to examine the uptake of free ¹⁸F-FDHT and SHBG-bound ¹⁸F-FDHT. Both ligands were examined for stability and competitive binding to androgen receptor over time in vitro prior to in vivo studies. [J Nucl Med] Abstract

Quantitative Proteomics of TRAMP Mice Combined with Bioinformatics Analysis Reveals That PDGF-B Regulatory Network Plays a Key Role in Prostate Cancer Progression

The authors demonstrated that crenolanib, a novel platelet-derived growth factor B (PDGF-B) receptor inhibitor, inhibited prostate cancer cell proliferation in a dose-dependent manner. [J Proteome Res] Abstract

Luteolin Attenuates Wnt Signaling via Upregulation of FZD6 to Suppress Prostate Cancer Stemness Revealed by Comparative Proteomics

Researchers report that luteolin suppresses prostate cancer (PCa) stemness through Wnt signaling by upregulation of frizzled class receptor 6 (FZD6). Luteolin inhibited PCa cell proliferation, migration, self-renewal as well as the expression of prostate cancer stem cell markers in vitro. [Sci Rep] Full Article

Characterization of Novel Cell Lines Derived from a MYC‐Driven Murine Model of Lethal Metastatic Adenocarcinoma of the Prostate

The authors report on the generation of two mouse prostate cancer cell lines, BMPC1 and BMPC2, derived from a lymph node, and liver metastasis, respectively. [Prostate] Abstract

Treating Metastatic Prostate Cancer with MicroRNA-145

A decrease in MYC and RAS expression was observed in all cell lines after treatment with miR-145, although statistical significance was achieved only in experiments with LNCaP and PC3 cell lines, with a decrease in 56% and 31% of RAS expression, respectively. [Apoptosis] Abstract

Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies

The authors focus on recent advances in our understanding of castration-resistant neuroendocrine prostate cancer (CRPC-NE) biology, the transdifferentiation/plasticity process, and development and characterization of relevant CRPC-NE preclinical models. [Cold Spring Harb Perspect Med] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Lynparza in Combination with Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck & Co., Inc. presented data, which showed clinical improvement in median radiologic progression-free survival with Lynparza in combination with abiraterone compared to abiraterone monotherapy, a standard of care, in metastatic castration-resistant prostate cancer. [Press release from AstraZeneca discussing research presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Major Trial Is First to Show Benefits of Immunotherapy in Some Men with Prostate Cancer

A major clinical trial has become the first to show benefits of immunotherapy in prostate cancer – for some men with advanced, otherwise untreatable disease. Researchers showed that a subset of men who had run out of all existing options for treatment survived much longer than expected when taking immunotherapy. [Press release from The Institute of Cancer Research discussing research presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Sensei Biotherapeutics Reports New Data from Phase I Clinical Trial of SNS-301

Sensei Biotherapeutics, Inc. announced the publication of data from the company’s multi-center Phase I clinical trial to assess safety and immunogenicity of SNS-301 in patients with biochemically recurrent prostate cancer. [Press release from Sensei Biotherapeutics, Inc. discussing research presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Prostate Cancer Drug Given Initial ‘No’ for NHS in England

A prostate cancer drug has been provisionally rejected as a first-line treatment on the NHS in England. The draft recommendation from the National Institute for Health and Care Excellence means abiraterone won’t be made routinely available for men with newly diagnosed prostate cancer that has spread to other parts of the body. [Cancer Research UK] Press Release

New Center for Advanced Regenerative Engineering Launches

Northwestern’s newest center has officially launched with a bold mission and interdisciplinary mindset. The Center for Advanced Regenerative Engineering aims to create an ecosystem that enables researchers and clinicians to regenerate tissues and organs for adult and pediatric patients. [Northwestern University] Press Release

Go for Launch: A Former Astronaut Becomes Spain’s Science Minister

Spain has a ministry of science again—and none other than the first Spanish astronaut is leading it. The new transition government led by socialist Pedro Sánchez announced that Pedro Duque, who visited space twice, will be at the helm of the newly created Ministry for Science, Innovation, and Universities. The announcement was cheered by the Spanish scientific community, which has long suffered from declining budgets and bureaucratic hurdles. [ScienceInsider] Editorial

Scientists Fare Poorly in Super Tuesday Primary Vote

Science-minded candidates seeking seats in the next U.S. Congress took a drubbing from their Democratic opponents in a raft of primary elections across the country. [ScienceInsider] Editorial

Chile, Keen to Become a Knowledge Society, Creates a Ministry of Science

Scientists in Chile have welcomed a decision by Congress to create a science ministry. Many researchers hope that a dedicated ministry will give science more prominence and better-coordinated policies—provided the ministry’s budget matches the government’s ambitions to “bring Chile towards an information and knowledge society,” as Gonzalo Blumel, the country’s minister secretary-general of the presidency, put it in a statement issued after the 31 May vote. [ScienceInsider] Editorial

EU to World: Join Our €100-Billion Research Program

The European Commission has outlined how it plans to spend the biggest research and innovation budget in its history. In a document that sets out plans for its next major science-funding program, the Commission also confirmed new rules that will, for the first time, allow any country in the world — including a post-Brexit United Kingdom — to take part. [Nature News] Editorial

NEW Cell Symposia: Translation of Stem Cells to the Clinic: Challenges and Opportunities
December 2-4, 2018
Los Angeles, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Positions – Ribosome Modifications (University of Copenhagen)

Research Fellow – Prostate Cancer (Sechenov University)

Postdoctoral Position – Steroid Hormone Production and Signaling (University of Rochester Medical Center)

Postdoctoral Positions – Transcriptional/Epigenetic Regulation in Cancer Progression (UT Health San Antonio)

Postdoctoral Fellow/Research Scientists – Prostate Cancer Research (Institute of Oncology Research – Universita della Svizzera Italiana)

Postdoctoral Position – Drug Discovery for Advance Prostate Cancer (Lerner Research Institute – Cleveland Clinic)

Postdoctoral Fellow – Computational Genomics of Cancer (Cold Spring Harbor Laboratory)

Research Associate – Computational Biology (University College London)

Academic Position – Cancer Research (Cedars-Sinai Medical Center)

Postdoctoral Fellow – Prostate Cancer (Moffitt Cancer Center)

Postdoctoral Associate – Prostate Research (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.